Novel activities of safe-in-human broad-spectrum antiviral agents
Ianevski, A., Zusinaite, E., Kuivanen, S., Strand, M., Lysvand, H., Teppor, M., Kakkola, L., Paavilainen, H., Laajala, M., Kallio-Kokko, H., Valkonen, M., Kantele, A., Telling, K., Lutsar, I., Letjuka, P., Metelitsa, N., Oksenych, V., Bjørås, M., Nordbø, S. A., . . . Kainov, D. (2018). Novel activities of safe-in-human broad-spectrum antiviral agents. Antiviral Research, 154, 174-182. https://doi.org/10.1016/j.antiviral.2018.04.016
Published in
Antiviral ResearchDate
2018Copyright
© 2018 Elsevier B.V. This is a final draft version of an article whose final and definitive form has been published by Elsevier. Published in this repository with the kind permission of the publisher.
According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley fever virus. Thus, the spectrum of antiviral activities of existing antiviral agents could be expanded towards other viral diseases.
Publisher
ElsevierISSN Search the Publication Forum
0166-3542Keywords
Publication in research information system
https://converis.jyu.fi/converis/portal/detail/Publication/28022402